Narendranath Epperla
Rating: 4.9 of 5
( out of 41 reviews )

Narendranath Epperla, MD, MS, FACP

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

  • Dr. Narendranath Epperla is an Associate Professor in the Division of Hematology and Hematologic Malignancies, Department of Medicine, at the Huntsman Cancer Institute - University of Utah. He is the Associate Chief of Clinical Research and Director of Phase 1 Clinical Trials program – Hematologic Malignancies. He specializes in treating patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) including CNS lymphomas and Waldenström macroglobulinemia. .

    Dr. Epperla is actively involved in cancer research. His research interests focus on conducting early phase clinical trials using novel drug combinations to treat patients with lymphoid malignancies and identify blood-based biomarkers that can predict treatment response. He is the national principal investigator on several investigator initiated trials and consortium studies. He is an active participant within the Alliance Lymphoma Committee and the National Clinical Trials Network.

    Dr. Epperla is a member of several professional organizations, including the American Society of Hematology, American Society of Clinical Oncology, American Society for Transplantation and Cellular Therapy, and the American Association for Cancer Research. He has authored over 185 peer-reviewed publications and is on the editorial board of several high-impact journals such as Journal of Hematology and Oncology, BMC Medicine, and Frontiers in Immunology.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 41 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very nice easy to talk to talked to me in layman's terms so I could understand

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Epperla is very Dr Epperla has a great way of explaining disease in a way that is easy to understand and makes a person feel confident of his skills.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Epperla is a stud! He has been everything you would ask from your physician; very professional knowledgeable, kind, and extremely concerned about my on going mental and physical state during treatment. He takes the time to break down technical aspects of my treatment into understandable terms and walks me through what to expect. I will be forever indebted to him for his support and care.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Epperla explained every step that needed to be taken in my treatment and also answered every question my wife had. He was very aggressive in the treatment plan and hit the ground running at full speed and did not stop. He and his staff have been the best blessing we could have asked for.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Epperla was personable and knowledgeable, and took the time to explain information in understandable terminology. I am happy we chose Huntsman for my care!

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very nice experience

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He's caring and very knowledgable. I feel I am getting the best of care with Dr. Epperla and his team.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Waited from 11.20 am until about 2pm. Delays happen but need to be planned for in the scheduled number of appointments. Was much too long and needed protein to eat

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Epperla is very good at what he does. My mother has improved a lot since he diagnosed her with lymphoma. He makes himself easy to understand, and when I ask him something, he doesn't leave me with any doubts. He's very kind and always smiling, which I really appreciate. His team is also very nice, including his assistant Sara and his nurse. Thank you for helping my mother with her illness. [TRANSLATED]

  • Dr. Narendranath Epperla is an Associate Professor in the Division of Hematology and Hematologic Malignancies, Department of Medicine, at the Huntsman Cancer Institute - University of Utah. He is the Associate Chief of Clinical Research and Director of Phase 1 Clinical Trials program – Hematologic Malignancies. He specializes in treating patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) including CNS lymphomas and Waldenström macroglobulinemia. .

    Dr. Epperla is actively involved in cancer research. His research interests focus on conducting early phase clinical trials using novel drug combinations to treat patients with lymphoid malignancies and identify blood-based biomarkers that can predict treatment response. He is the national principal investigator on several investigator initiated trials and consortium studies. He is an active participant within the Alliance Lymphoma Committee and the National Clinical Trials Network.

    Dr. Epperla is a member of several professional organizations, including the American Society of Hematology, American Society of Clinical Oncology, American Society for Transplantation and Cellular Therapy, and the American Association for Cancer Research. He has authored over 185 peer-reviewed publications and is on the editorial board of several high-impact journals such as Journal of Hematology and Oncology, BMC Medicine, and Frontiers in Immunology.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor
    Academic Divisions Hematology & Hematologic Malignancies

    Education history

    Professional Medical Medicine, Surgery - Kamineni Institute of Medical Sciences M.B.B.S.
    Internship Internal Medicine - Marshfield Clinic/Ministry Saint Joseph¿s Hospital Intern
    Residency Internal Medicine - Marshfield Clinic/Ministry Saint Joseph¿s Hospital Resident
    Chief Resident Internal Medicine - Marshfield Clinic/Ministry Saint Joseph¿s Hospital Chief Resident
    Fellowship Hematology/Oncology - Medical College of Wisconsin Fellow
    Graduate Training Clinical and Translational Science Institute of Southeast Wisconsin, Medical College of Wisconsin M.S.

    Selected Publications

    Journal Article

    1. Kasirye Y, Manne JR, Epperla N, Bapani S, Garcia-Montilla (2012). Apical hypertrophic cardiomyopathy presenting as recurrent unexplained syncope. Clinical medicine & research, 10(1), 26-31. (Read full publication)
    2. Kasirye Y, Danhof RS, Epperla N, Garcia-Montilla R (2011). Sweet's syndrome: one disease, multiple faces. Clinical medicine & research, 9(3-4), 134-6. (Read full publication)
    3. Kasirye Y, Epperla N, Manne JR, Bapani S, Garcia-Montilla R (2012). Brain abscesses complicating acute pneumococcal meningitis during etanercept therapy. Clinical medicine & research, 10(4), 230-5. (Read full publication)
    4. Bapani S, Epperla N, Kasirye Y, Mercier R, Garcia-Montilla (2013). ADAMTS13 deficiency and thrombotic thrombocytopenic purpura associated with trimethoprim-sulfamethoxazole. Clinical medicine & research, 11(2), 86-90. (Read full publication)
    5. Wagner BP, Epperla N, Medina-Flores (2013). Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. Diagnostic pathology, 8, 192. (Read full publication)
    6. Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale S (2013). Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ, 112(6), 244-9; quiz 250. (Read full publication)
    7. Epperla N, Brilliant MH, Vidaillet (2014). Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ case reports, 2014, (Read full publication)
    8. Epperla N, McKiernan FE, Kenney C (2014). Radiographic findings in Waldenström's macroglobulinemia resembling fibrogenesis imperfecta ossium (FIO): a case report. Skeletal radiology, 43(3), 381-5. (Read full publication)
    9. Epperla N, McKiernan F (2014). An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis. Skeletal radiology, 43(9), 1313-8. (Read full publication)
    10. Epperla N, Landeck J, Sabbagh (2014). Osmotic demyelination syndrome. WMJ, 113(5), 197-8. (Read full publication)
    11. Epperla N, Medina-Flores R, Mazza JJ, Yale S (2014). Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy. WMJ, 113(6), 242-5. (Read full publication)
    12. Epperla N, Usoltseva (2014). Unprovoked deep venous thrombosis in a young adult associated with membranous obstruction of inferior vena cava. BMJ case reports, 2014, (Read full publication)
    13. Epperla N, Hocking (2015). Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clinical medicine & research, 13(1), 32-5. (Read full publication)
    14. Epperla N, Kattamanchi S, Fritsche T (2015). Appearances are Deceptive: Staphylococcus Superinfection of Clavicular Tuberculous Osteomyelitis. Clinical medicine & research, 13(2), 85-8. (Read full publication)
    15. Epperla N, Peterson E, Foy (2015). An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. BMC hematology, 15, 7. (Read full publication)
    16. Epperla N, George (2016). An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. Journal of gastrointestinal cancer, 47(2), 206-9. (Read full publication)
    17. Epperla N, McKiernan (2015). Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. SpringerPlus, 4, 455. (Read full publication)
    18. Epperla N, Pathak (2015). Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level. WMJ, 114(4), 163-6; quiz 167. (Read full publication)
    19. Jayarangaiah A, Epperla (2015). Early recognition is the key to success: pulseless electrical activity (PEA) as a manifestation of heparin-induced anaphylactoid reaction. BMJ case reports, 2015, (Read full publication)
    20. Epperla N, Hemauer K, Friedman KD, George JN, Foy (2016). Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. American journal of hematology, 91(6), 644-6. (Read full publication)
    21. Strouse C, Epperla (2017). A rash diagnosis: Gemcitabine-associated pseudocellulitis. Journal of oncology pharmacy practice, 23(2), 157-160. (Read full publication)
    22. Epperla N, Strouse C, VanSandt AM, Foy (2016). Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah's Witness treated with hemoglobin concentrate complicated by achalasia. Transfusion, 56(7), 1801-6. (Read full publication)
    23. Epperla N, Weissman D (2016). Chemotherapy: Response and Survival Data #99. Journal of palliative medicine, 19(9), 1011. (Read full publication)
    24. Epperla N, Harrington AM, Hemauer K, Shah N (2016). Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. American journal of hematology, 91(11), 1161-1164. (Read full publication)
    25. Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani (2016). Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. Bone marrow transplantation, 51(12), 1602-1604. (Read full publication)
    26. Epperla N, Olteanu H, Hamadani (2016). Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. British journal of haematology, 175(5), 758. (Read full publication)
    27. Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske T (2016). Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia, 16(12), 672-678. (Read full publication)
    28. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani (2017). Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. American journal of hematology, 92(2), 161-170. (Read full publication)
    29. Dang G, Epperla N, Muppidi V, Sahr N, Pan A, Simpson P, Baumann Kreuziger (2017). Medical Management of Pump-Related Thrombosis in Patients with Continuous-Flow Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. ASAIO journal (American Society for Artificial Internal Organs, 63(4), 373-385. (Read full publication)
    30. Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske T (2017). Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematological oncology, 35(4), 528-535. (Read full publication)
    31. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani (2017). Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clinical lymphoma, myeloma & leukemia, 17(5), 305-311.e2. (Read full publication)
    32. Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig T (2017). Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. British journal of haematology, 178(3), 427-433. (Read full publication)
    33. Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske T (2017). Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia, 17(7), 408-414. (Read full publication)
    34. Epperla N, Ye F, Idris A, Sakkalaek A, Liang H, Chyou PH, Dart RA, Mazza J, Yale (2017). Treatment-Related Cardiovascular Outcomes in Patients with Symptomatic Subclavian Artery Stenosis. Cureus, 9(5), e1262. (Read full publication)
    35. Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani (2017). Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. Journal of hematology & oncology, 10(1), 117. (Read full publication)
    36. Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger L (2017). Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion, 57(11), 2775-2781. (Read full publication)
    37. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa L (2017). C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. Cancer, 123(22), 4411-4418. (Read full publication)
    38. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani (2018). Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of blood and marrow transplantation, 24(1), 78-85. (Read full publication)
    39. Xavier AC, Epperla N, Taub JW, Costa L (2018). Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults. American journal of hematology, 93(2), 238-245. (Read full publication)
    40. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda (2018). R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. British journal of haematology, 180(4), 534-544. (Read full publication)
    41. Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova (2018). Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation, 24(5), 983-988. (Read full publication)
    42. Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen J (2018). Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer, 124(11), 2306-2315. (Read full publication)
    43. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani (2018). Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood advances, 2(8), 933-940. (Read full publication)
    44. Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen J (2018). Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Leukemia & lymphoma, 59(12), 2862-2870. (Read full publication)
    45. Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa L (2019). Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leukemia & lymphoma, 60(4), 940-946. (Read full publication)
    46. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla (2019). Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clinical lymphoma, myeloma & leukemia, 19(2), 95-102. (Read full publication)
    47. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani (2019). Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. Journal of hematology & oncology, 12(1), 6. (Read full publication)
    48. Epperla N, Shana'ah AY, Jones D, Christian BA, Ayyappan S, Maddocks K, Woyach J (2019). Resistance mechanism for ibrutinib in marginal zone lymphoma. Blood advances, 3(4), 500-502. (Read full publication)
    49. Guo S, Jiang S, Epperla N, Ma Y, Maadooliat M, Ye Z, Olson B, Wang M, Kitchner T, Joyce J, An P, Wang F, Strenn R, Mazza JJ, Meece JK, Wu W, Jin L, Smith JA, Wang J, Schrodi S (2019). A gene-based recessive diplotype exome scan discovers FGF6, a novel hepcidin-regulating iron-metabolism gene. Blood, 133(17), 1888-1898. (Read full publication)
    50. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske T (2019). Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood advances, 3(11), 1661-1669. (Read full publication)
    51. Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar (2019). Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. Cancer, 125(24), 4417-4425. (Read full publication)
    52. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske T (2020). Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood advances, 4(1), 47-54. (Read full publication)
    53. Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani (2020). Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 126(10), 2279-2287. (Read full publication)
    54. Epperla N, Pavilack M, Olufade T, Bashyal R, Li J, Kabadi SM, Yuce H, Andritsos (2020). Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis. Orphanet journal of rare diseases, 15(1), 47. (Read full publication)
    55. Palmer JD, Bhamidipati D, Shukla G, Epperla N, Glass J, Kim L, Shi (2020). Outcomes after stereotactic radiosurgery for CNS lymphoma. Journal of neuro-oncology, 147(2), 465-476. (Read full publication)
    56. Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini (2020). Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. British journal of haematology, 189(6), 1171-1181. (Read full publication)
    57. Epperla (2020). What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid. British journal of haematology, 190(4), 490-492. (Read full publication)
    58. Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani (2020). Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA oncology, 6(7), 1011-1018. (Read full publication)
    59. Epperla N, Vaughn JL, Othus M, Hallack A, Costa L (2020). Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?. Cancer medicine, 9(15), 5519-5525. (Read full publication)
    60. Evens AM, Danilov A, Jagadeesh D, Sperling A, Kim SH, Vaca R, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein AK, Blum KA, Boughan KM, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Ramdial J, Maliske SM, Epperla N, Venugopal P, Feldman TA, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning MA, Caimi P, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio J (2021). Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood, 137(3), 374-386. (Read full publication)
    61. Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani (2021). Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transplantation and cellular therapy, 27(1), 58-66. (Read full publication)
    62. Thangavadivel S, Zhao Q, Epperla N, Rike L, Mo X, Badawi M, Bystry DM, Phelps MA, Andritsos LA, Rogers KA, Jones J, Woyach JA, Byrd JC, Awan F (2020). Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical cancer research, 26(23), 6187-6195. (Read full publication)
    63. Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens A (2021). Burkitt Lymphoma International Prognostic Index. Journal of clinical oncology, 39(10), 1129-1138. (Read full publication)
    64. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski A (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942. (Read full publication)
    65. Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger T (2021). Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical cancer research, 27(12), 3339-3350. (Read full publication)
    66. Vaughn JL, Spies D, Xavier AC, Epperla (2021). Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States. American journal of hematology, 96(7), 816-822. (Read full publication)
    67. Choueiry F, Singh S, Sircar A, Laliotis G, Sun X, Chavdoula E, Zhang S, Helmig-Mason J, Hart A, Epperla N, Tsichlis P, Baiocchi R, Alinari L, Zhu J, Sehgal (2021). Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. Cancers, 13(9), (Read full publication)
    68. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter C (2021). Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA oncology, 7(7), 993-1003. (Read full publication)
    69. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen J (2021). Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. European journal of haematology, 107(3), 301-310. (Read full publication)
    70. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen J (2021). Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. American journal of hematology, 96(11), 1374-1384. (Read full publication)
    71. D'Angelo CR, Hanel W, Chen Y, Yu M, Yang D, Guo L, Karmali R, Burkart M, Ciccosanti C, David K, Risch Z, Murga-Zamalloa C, Devata S, Wilcox R, Savani M, Courville EL, Bachanova V, Rabinovich E, Peace D, Osman F, Epperla N, Kenkre V (2021). Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis. Hematological oncology, 39(4), 473-482. (Read full publication)
    72. Vaughn JL, Soroka O, Epperla N, Safford M, Pinheiro L (2021). Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. Cancer medicine, 10(20), 7330-7338. (Read full publication)
    73. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen J (2021). Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood advances, 5(23), 5179-5189. (Read full publication)
    74. Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith S (2021). Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. British journal of haematology, 195(5), 757-763. (Read full publication)
    75. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli (2022). Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone marrow transplantation, 57(7), 1150-1163. (Read full publication)
    76. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla (2022). Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. Hematological oncology, 40(1), 48-56. (Read full publication)
    77. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian BA, Baiocchi RA, Maddocks K, Sawalha (2022). Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas. Blood advances, 6(2), 460-472. (Read full publication)
    78. Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos I (2022). An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood advances, 6(7), 2035-2044. (Read full publication)
    79. Voorhees TJ, Epperla (2022). Identifying aggressive subsets within diffuse large B-cell lymphoma: implications for treatment approach. Expert review of anticancer therapy, 22(5), 523-533. (Read full publication)
    80. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli (2022). Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplantation and cellular therapy, 28(6), 335.e1-335.e17. (Read full publication)
    81. Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos L (2022). Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia. Leukemia research, 120, 106919. (Read full publication)
    82. Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, Alinari L, Brammer J, Christian B, Baiocchi RA, Maddocks K, Sawalha (2022). Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study. Therapeutic advances in hematology, 13, 20406207221112900. (Read full publication)
    83. Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever (2022). Development of a distributed international patient data registry for hairy cell leukemia. Leukemia & lymphoma, 63(13), 3021-3031. (Read full publication)
    84. Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali (2023). Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood advances, 7(12), 2657-2669. (Read full publication)
    85. Epperla N, Reljic T, Chowdhury SM, Ferreri AJM, Kumar A, Hamadani (2023). Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis. Hematological oncology, 41(1), 88-96. (Read full publication)
    86. Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse (2023). Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood advances, 7(1), 88-91. (Read full publication)
    87. Annunzio K, Cackovic M, Bond D, Sawalha Y, Voorhees TJ, Hanel W, Alinari L, Baiocchi R, Reneau J, Brammer J, Maddocks K, Christian B, Epperla (2023). Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy. Blood advances, 7(10), 2241-2244. (Read full publication)
    88. Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever (2022). Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood cancer journal, 12(12), 165. (Read full publication)
    89. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen J (2023). Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood advances, 7(11), 2287-2296. (Read full publication)
    90. Azar JH, Evans JP, Sikorski MH, Chakravarthy KB, McKenney S, Carmody I, Zeng C, Teodorescu R, Song NJ, Hamon JL, Bucci D, Velegraki M, Bolyard C, Weller KP, Reisinger SA, Bhat SA, Maddocks KJ, Denlinger N, Epperla N, Gumina RJ, Vlasova AN, Oltz EM, Saif LJ, Chung D, Woyach JA, Shields PG, Liu SL, Li Z, Rubinstein M (2023). Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI insight, 8(6), (Read full publication)
    91. Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla (2023). Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. Cancer medicine, 12(7), 8228-8237. (Read full publication)
    92. Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari (2023). A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. Cancers, 15(5), (Read full publication)
    93. Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia & lymphoma, 64(5), 1026-1034. (Read full publication)
    94. David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens A (2023). Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. American journal of hematology, 98(6), 900-912. (Read full publication)
    95. McKenna M, Epperla N, Ghobadi A, Liu J, Lazaryan A, Ibrahim U, Jacobson CA, Naik SG, Nastoupil L, Chowdhury SM, Voorhees TJ, Jacobs MT, Farooq U, Osman K, Olszewski AJ, Ahmed S, Evens A (2023). Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD. British journal of haematology, 202(2), 248-255. (Read full publication)
    96. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski A (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood advances, 7(21), 6381-6394. (Read full publication)
    97. Epperla N, Zhao Q, Karmali R, Torka P, Shea L, Oh TS, Anampa-Guzmán A, Reves H, Tavakkoli M, Greenwell IB, Hansinger E, Umyarova E, Annunzio K, Sawalha Y, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Grover NS, Olszewski A (2023). Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood advances, 7(17), 5038-5046. (Read full publication)
    98. Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani (2023). ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplantation and cellular therapy, 29(9), 548-555. (Read full publication)
    99. Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal (2023). Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia, 37(10), 2094-2106. (Read full publication)
    100. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda (2023). Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood advances, 7(21), 6630-6638. (Read full publication)
    101. Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee H (2023). Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood advances, 7(24), 7485-7493. (Read full publication)
    102. Melody M, Epperla N, Shouse G, Romancik JT, Allen PB, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Herr MM, Odetola O, Lin AY, Moreira J, Ma S, Winter JN, Roy I, Stephens DM, Danilov AV, Shah NN, Barta SK, Cortese MJ, Cohen J, Gordon LI, Karmali (2024). Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy. Blood advances, (Read full publication)
    103. Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, Habib A, Kola-Kehinde O, Ruz P, Khan S, Sharma S, Meara A, Mahmood S, Feldman S, Yang EH, Kim J, Epperla N, Addison (2024). Cardiovascular toxicities associated with bispecific T-cell engager therapy. Journal for immunotherapy of cancer, 12(2), (Read full publication)
    104. Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan FT, Dholaria BR, Maakaron JE, Sandoval-Sus JD, Mishra R, Saha A, Annunzio K, Bhaskar ST, Sumransub N, Fijalka A, Ivanov SA, Lin Y, Kharfan-Dabaja M (2024). Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone marrow transplantation, 59(2), 211-216. (Read full publication)
    105. Dhir A, Epperla N, Costa LJ, Xavier A (2023). Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma. Frontiers in public health, 11, 1261066. (Read full publication)
    106. Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson C (2024). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood, 143(6), 496-506. (Read full publication)
    107. Rezazadeh A, Szabo A, Khurana A, Inwards DJ, Lunning MA, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Monahan K, Siker M, King DM, Fenske T (2023). Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study. Haematologica, (Read full publication)
    108. Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzmán A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Ramakrishnan Geethakumari P, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood advances, 7(22), 6839-6843. (Read full publication)
    109. Nalin A, Zhao Q, Voorhees T, Bond D, Sawalha Y, Hanel W, Sigmund A, Annunzio K, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia. Frontiers in oncology, 13, 1264387. (Read full publication)
    110. Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein P, Chaudhry A, Olszewski A (2024). High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood advances, 8(20), 5355-5364. (Read full publication)
    111. Bommier C, Link BK, Gysbers BJ, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson CA, Chihara D, Alderuccio JP, Koff JL, Epperla N, Conconi A, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan J (2024). Transformation in Marginal Zone Lymphoma: Results from a Prospective Cohort and a Meta-Analysis of the Literature. Blood advances, (Read full publication)
    112. Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, Barta SK, Caimi PF, Sethi TK, Reddy N, Karmali R, Bello C, Chavez JC, Kothari SK, Hernandez-Ilizaliturri FJ, Svoboda J, Lansigan F, Glenn MJ, Cohen JB, Sorge C, Christian B, Herrera AF, Hamadani M, Costa LJ, Xavier A (2024). Evaluation of prognostic factors for high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood advances, (Read full publication)
    113. Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon L (2024). Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood advances, 8(10), 2592-2599. (Read full publication)
    114. Grover NS, Annunzio K, Watkins M, Torka P, Karmali R, Anampa-Guzmán A, Oh TS, Reves H, Tavakkoli M, Hansinger E, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla (2024). Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study. Blood cancer journal, 14(1), 182. (Read full publication)
    115. Munir M, Sayed A, Addison D, Epperla (2024). Cardiovascular Toxicities Associated with Novel Cellular Immune Therapies. Blood advances, (Read full publication)
    116. Bajwa A, Zhao Q, Geer MJ, Lin C, Westholder J, Maakaron J, Ghosh M, Frame DG, Galal A, Tossey J, Ahmed N, Bezerra ED, Denlinger N, de Lima MJ, Epperla N, Caimi PF, Voorhees TJ (2024). Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Related CRS and ICANS - A Multicenter Retrospective Analysis. Blood Advances,
    117. Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers E (2025). Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica, 110(3), 706-714. (Read full publication)
    118. Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch RC, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared JA, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik AP, Hill BT, Kamdar M, Ortiz-Maldonado V, Martínez-Cibrian N, Shune L, Shadman (2025). Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma. Blood, (Read full publication)
    119. Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla (2024). A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. Blood cancer journal, 14(1), 212. (Read full publication)
    120. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen (2024). Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood cancer journal, 14(1), 210. (Read full publication)
    121. Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla (2025). Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers. Blood cancer journal, 15(1), 45. (Read full publication)
    122. Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla (2025). Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood cancer journal, 15(1), 43. (Read full publication)
    123. Borja-Montes OF, Bode A, Escobar-Gil T, Toro-Pedroza A, Epperla N, Andritsos L (2025). Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years. EJHaem, 6(3), e70065. (Read full publication)
    124. Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen (2025). How well does loncastuximab tesirine work after chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma? A plain language summary of a real-world evidence study. Future oncology (London, England), 1-10. (Read full publication)
    125. Torka P, Grover NS, Voorhees TJ, Karmali R, Annunzio K, Watkins MP, Anampa-Guzmán A, Reves H, Tavakkoli M, Christian B, Thomas C, Barta SK, Geethakumari PR, Bartlett NL, Shouse G, Olszewski AJ, Epperla (2025). Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study. Hematological oncology, 43(3), e70087. (Read full publication)
    126. Aqeel SB, Faisal MS, Akhtar OS, Attwood K, George A, Advani P, Epperla N, Torka (2024). Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis. Annals of hematology & oncology,
    127. St-Pierre F, Bhatta S, Doukas PG, Jenkin M, Annunzio K, Rojek AE, Gibson A, Tiger YK, McCall B, Alhamad K, Hansen A, Alderuccio JP, Adewale O, Patel K, Trabolsi A, Lossos IS, Fitzgerald L, Ollila TA, Matasar MJ, Kline J, Karmali R, Epperla (2025). Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. Blood cancer journal, 15(1), 110. (Read full publication)
    128. Sharp J, Shana'ah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla (2025). Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. Journal of the National Comprehensive Cancer Network, 1-5. (Read full publication)
    129. Annunzio K, Grover NS, Welkie RL, Torka P, Watkins MP, Anampa-Guzman A, Tavakkoli M, Oh TS, Reves H, Jones D, Hanel W, Christian B, Geethakumari PR, Karmali R, Barta SK, Bartlett NL, Olszewski AJ, Epperla (2023). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study. Blood Advances, (2023) 7 (22), 6839-6843.
    130. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski A (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood advances, 7(21), 6381-6394. (Read full publication)
    131. Sharp J, Zhao Q, Voorhees TJ, Bond DA, Sawalha Y, Reneau J, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Brammer JE, Maddocks K, Christian B, Bezerra E, Denlinger N, Vasu S, De Lima M, Prosek J, Epperla (2025). Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma. British journal of haematology, (Read full publication)
    132. Cappelli L, Kayne A, Newman J, Elguindy A, Epperla N, Palmer JD, Outschoorn UM, Porcu P, Shi W, Alnahhas (2025). Primary central nervous system lymphoma: Predictors of response to induction therapy and patterns of progression. Neuro-oncology advances, 7(1), vdaf082. (Read full publication)
    133. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski (2021). HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood advances, 5(14), 2852-2862. (Read full publication)
    134. Annunzio K, Bhatta S, Hanel W, Zhao Q, Owen M, Rosen H, Voorhees TJ, Bond DA, Sawalha Y, Sigmund AM, Alinari L, Baiocchi RA, Maddocks KJ, Jones D, Christian B, Epperla (2024). Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients. Hematological oncology, 42(3), e3278. (Read full publication)
    135. Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz RM, Miao J, Song C, Wu D, Chan WK, Bezerra E, Epperla N, Voorhees TJ, Brammer J, Kittai AS, Bond DA, Sawalha Y, Sigmund A, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks K, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski S, Li Z, Huang X, Yang (2024). Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma. Blood advances, 8(12), 3140-3153. (Read full publication)
    136. Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez (2024). Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia, 38(7), 1564-1569. (Read full publication)
    137. Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, Kanakry JA, Lekakis L, Kharfan-Dabaja MA, Scordo M, Riedell PA, Jain T, Shadman M, Sauter C, Hamadani M, Herrera AF, Ahmed (2024). Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. British journal of haematology, 205(3), 1202-1207. (Read full publication)
    138. Kapoor N, Zhao Q, Stiff A, Bhat SA, Anghelina MI, Andritsos LA, Blachly JS, Epperla N, Boghdadly ZE, Grever MR, Rogers K (2024). Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia. EJHaem, 5(5), 1005-1009. (Read full publication)
    139. Aqeel SB, Faisal MS, Akhtar OS, Attwood K, George A, Advani P, Epperla N, Torka (2024). Racial and ethnic disparities in outcomes of diffuse large B cell lymphoma in adolescent and young adults: a SEER database analysis. Annals of hematology, 103(12), 5539-5547. (Read full publication)
    140. Bajwa A, Zhao Q, Geer M, Lin C, Westholder J, Maakaron J, Ghosh M, Frame D, Galal A, Tossey J, Ahmed N, Bezerra E, Denlinger N, de Lima M, Epperla N, Caimi P, Voorhees (2025). Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis. Blood advances, 9(1), 170-175. (Read full publication)
    141. Kharfan-Dabaja MA, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, Yared J, Ahmed N, Hamadani M, Beitinjaneh A, Narkhede M, Jagadeesh D, Ramakrishnan Geethakumari P, Dholaria B, Gergis U, Munoz J, Sandoval-Sus J, Locke FL, Fein J, Khurana A, Ayala E, Annunzio K, Rapoport AP, Lutfi F, Akhtar OS, Lekakis L, Mehta A, Oluwole OO, Logue J, Jain MD, Shore T, Durani U, Alhaj Moustafa M, McGuirk J, Lin Y, Yamshon S, Chavez J (2025). Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study. Bone marrow transplantation, 60(5), 632-639. (Read full publication)
    142. LeHanka AM, Kebede AM, Amirmokhtari N, Stanek JR, Willen F, Yeager N, Christian B, Epperla N, Sawalha Y, Sigmund AM, Brammer JE, Voorhees TJ, Reneau JC, Baiocchi RA, Maddocks KJ, Cairo MS, Audino AN, Bond D (2025). Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B-Cell Lymphomas Treated at an Adult Versus Pediatric Cancer Center. Pediatric blood & cancer, 72(6), e31664. (Read full publication)
    143. Epperla N, Olszewski AJ, Ayers EC, Ahmed (2025). Management of Adverse Reactions to Loncastuximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Hematological oncology, 43(5), e70128. (Read full publication)
    144. Sharp J, Olszewski AJ, Epperla (2025). Identifying high-risk patients with MALT lymphoma undergoing first-line therapy for disease progression. Expert review of hematology, (Read full publication)
    145. Thiruvengadam SK, Ahn KW, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera A (2025). CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis. American journal of hematology, (Read full publication)
    146. Altomare NJ, Herr MM, Nair NM, Stephens DM, Cohen JB, Epperla N, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin A, Ma S, Winter JN, Danilov A, Barta SK, Gordon LI, Romancik J, Grover NS, Karmali R, American BiTE and CART Consortiu (2025). Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART. Cancers, 17(14), (Read full publication)
    147. Kenkre VP, Lin Y, Epperla N, Rajguru SA, Chang JE, Pophali PA, Harris EI, Fletcher CD, Matasar M, Eltoukhy H, Bond DA, Sawalha Y, Christian B, Voorhees T, Endres M, Howard M, Bhavsar D, Fleming M, Carter JS, Evens A (2024). A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study. Blood (2024), 144(Supplement 1), 4415.
    148. Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens DM, Romancik JT, Cortese MJ, Bhansali RS, Moyo TK, Kenkre VP, Ollila TA, Hess BT, Fitzgerald LA, Shouse G, Matasar MJ, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover NS, Karmali (2025). Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium. Blood advances, (Read full publication)
    149. Melody M, Grover NS, Franco S, Romancik JT, Cortese MJ, Moyo TK, Bhansali RS, Ollila TA, Kenkre VP, Fitzgerald LA, Hess BT, Matasar MJ, Shouse G, Annunzio K, Herr MM, Davis JA, Jesme C, Pelcovits A, Moreira J, Ma S, Winter JN, Lin AY, Danilov AV, Roy I, Barta SK, Gordon LI, Stephens DM, Cohen JB, Epperla N, Karmali (2025). Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium. Blood advances, (Read full publication)
    150. S. Neelapu, J. Chavez, A. Sehgal, N. Epperla, M. Ulrickson, E. Bachy, P. Munshi, C. Casulo, D. Maloney, S. de Vos, R. Reshef, L. Leslie, O. Oluwole, I. Yakoub-Agha, R. Khanal, J. Rosenblatt, J. Wulff, R. Shen, W. Zhang, S. Poddar, H. Miao, O. Nikolajeva, C. Jacobso (2025). Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. American journal of clinical oncology, 0(JCO-25-00668),
    151. L. Cappelli, A. Kayne, J. Newman, A. Elguindy, N. Epperla, J. Palmer, U. Outschoorn, P. Porcu, W. Shi, I. Alnahha (2025). Primary CNS Lymphoma: Predictors of Response to induction Therapy and Patterns of Progression. Neuro-oncology advances, 7,
    152. K Saverno, KMZ Savill, B Feinberg, J Galvin, P Pathak, T Amoloja, N Epperla, LJ Nastoupi (2024). REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY PRIMARY REFRACTORY STATUS. Hematology, transfusion and cell therapy, 46(Supplement 4), S229.
    153. N Epperla, LJ Nastoupil, KMZ Savill, B Feinberg, J Galvin, P Pathak, T Amoloja, M Vukcevic, K Savern (2024). REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY AGE GROUP (>70 YEARS AND 70 YEARS). Hematology, transfusion and cell therapy, 46(Supplement 4), S226-S227.
    154. N Epperla, LJ Nastoupil, B Feinberg, J Galvin, P Pathak, T Amoloja, D Gentile, K Savern (2024). REAL-WORLD SEQUENTIAL USE OF CD19-DIRECTED THERAPIES FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAFASITAMAB PRECEDING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY. Hematology, transfusion and cell therapy, 46(Supplement 4), S226.
    155. L Cappelli, A Kayne, J Newman, M Sharif, A Elguindy, N Epperla, J Palmer, I Alnahhas, W Sh (2024). Patterns of Disease Progression in patients with newly diagnosed Primary Central Nervous System Lymphoma Following Treatment with High-Dose Methotrexate. Research square, Preprint Version 1,
    156. Olszewski AJ, Ollila TA, Chihara D, Shouse G, Grover N, Karmali R, Torka P, Thomas C, Geethakumari PR, Barta SK, Bartlett NL, Epperla (2025). Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma. Haematologica, (Read full publication)

    Review

    1. Manne JR, Kasirye Y, Epperla N, Garcia-Montilla R (2012). Non-cardiogenic pulmonary edema complicating electroconvulsive therapy: short review of the pathophysiology and diagnostic approach. Clinical medicine & research, 10(3), 131-6. (Read full publication)
    2. Jayarangaiah A, Sehgal R, Epperla (2014). Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature. BMC neurology, 14, 200. (Read full publication)
    3. Epperla N, Mazza JJ, Yale S (2015). A Review of Clinical Signs Related to Ecchymosis. WMJ, 114(2), 61-5. (Read full publication)
    4. Epperla N, Fenske TS, Hari PN, Hamadani (2015). Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. World journal of transplantation, 5(3), 81-8. (Read full publication)
    5. Epperla N, Fenske TS, Lazarus HM, Hamadani (2015). Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?. Bone marrow transplantation, 50(11), 1393-404. (Read full publication)
    6. Epperla N, Hamadani (2017). Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. Hematology/oncology and stem cell therapy, 10(4), 277-284. (Read full publication)
    7. Denlinger NM, Epperla N, William B (2018). Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer management and research, 10, 615-624. (Read full publication)
    8. Sircar A, Chowdhury SM, Hart A, Bell WC, Singh S, Sehgal L, Epperla (2020). Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. International journal of molecular sciences, 21(3), (Read full publication)
    9. Hanel W, Epperla (2020). Emerging therapies in mantle cell lymphoma. Journal of hematology & oncology, 13(1), 79. (Read full publication)
    10. Epperla N, Hamadani (2021). A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. Current hematologic malignancy reports, 16(1), 19-24. (Read full publication)
    11. Liu Q, Harris N, Epperla N, Andritsos L (2021). Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. OncoTargets and therapy, 14, 1797-1805. (Read full publication)
    12. Epperla N, Herrera A (2021). How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. Blood, 138(7), 520-530. (Read full publication)
    13. Hanel W, Epperla (2021). Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. Journal of hematology & oncology, 14(1), 104. (Read full publication)
    14. Epperla N, Hamadani (2021). Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. Hematology. American Society of Hematology. Education Program, 2021(1), 247-253. (Read full publication)
    15. Hanel W, Herrera AF, Epperla (2022). Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. Experimental hematology & oncology, 11(1), 108. (Read full publication)
    16. Jain N, Mamgain M, Chowdhury SM, Jindal U, Sharma I, Sehgal L, Epperla (2023). Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. Journal of hematology & oncology, 16(1), 99. (Read full publication)
    17. Shelley CS, Galiègue-Zouitina S, Andritsos LA, Epperla N, Troussard (2024). The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease. Leukemia & lymphoma, 66(4), 637-655. (Read full publication)
    18. Bock AM, Epperla (2025). Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. Journal of hematology & oncology, 18(1), 68. (Read full publication)

    Book Chapter

    1. Epperla N, Jayarangaiah A, Fenske T (2017). Hepatosplenic T-cell Lymphoma.
    2. Epperla N, Atallah (2017). Langerhans cell Histiocytosis and Histiocytic Sarcoma.
    3. Epperla N, Fenske T (2017). Mantle Cell Lymphoma.
    4. Epperla N, Hashmi H, Hamadani (2017). Indolent Lymphomas.
    5. Schneidewend R, Epperla N, Friedman (2017). Thrombotic Thrombocytopenia Purpura and the Hemolytic Uremic Syndrome.
    6. Epperla N, Hamadani M, Horowitz M (2017). Establishing a Hematopoietic Stem Cell Transplantation Unit: A Practical Guide.
    7. Epperla N, Hanel W, Talpaz (2022). Cytokines, Interferons and Hematopoietic Growth Factors.
    8. Epperla N, Herrera AF, Mei (2022). Hematopoietic cell transplantation in classical Hodgkin lymphoma.
    9. Walter H, Epperla (2025). Hepatosplenic T-cell Lymphoma. 491.

    Editorial

    1. Qian L, De Lima M, Mims AS, Epperla (2022). Editorial: Rising Stars in Hematologic Malignancies 2021. Frontiers in oncology, 12, 858564. (Read full publication)
    2. Hanel W, Epperla (2023). Another step toward frontline BTK inhibitor therapy in MCL. Blood advances, 7(23), 7358-7360. (Read full publication)
    3. Upshaw JN, Parson SK, Buchsbaum RJ, Schlam I, Ruddy KJ, Durani U, Epperla N, Leong D (2024). Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: JACC: CardioOncology Controversies in Cardio-Oncology. JACC. CardioOncology, 6(2), 322-324. (Read full publication)

    Letter

    1. Hebbring SJ, Slager SL, Epperla N, Mazza JJ, Ye Z, Zhou Z, Achenbach SJ, Vasco DA, Call TG, Rabe KG, Kay NE, Caporaso NE, Lanasa MC, Camp NJ, Strom SS, Goldin LR, Cerhan JR, Brilliant MH, Schrodi S (2013). Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. Blood, 121(1), 237-8. (Read full publication)
    2. Epperla N, Kapke JT, Karafin M, Friedman KD, Foy (2016). Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. American journal of hematology, 91(6), E313-4. (Read full publication)
    3. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani (2017). Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. Bone marrow transplantation, 52(1), 147-150. (Read full publication)
    4. Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse (2022). Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. Journal of hematology & oncology, 15(1), 96. (Read full publication)
    5. Epperla N, Hamadani M, Fenske TS, Costa L (2018). Incidence and survival trends in mantle cell lymphoma. British journal of haematology, 181(5), 703-706. (Read full publication)
    6. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah N (2017). Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. American journal of hematology, 92(10), E610-E611. (Read full publication)
    7. Epperla N, Kleman A, Karafin M, Foy (2018). Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?. Annals of hematology, 97(9), 1727-1729. (Read full publication)
    8. Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu (2019). Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. Bone marrow transplantation, 54(6), 913-916. (Read full publication)
    9. Vaughn JL, Pinheiro LC, Olszewski A, Epperla (2021). Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). American journal of hematology, 96(4), E123-E126. (Read full publication)
    10. Vaughn JL, Gundepalli SG, Epperla (2022). Racial differences in the survival of mantle cell lymphoma patients in the United States. Hematological oncology, 40(3), 479-481. (Read full publication)
    11. Epperla N, Zhao Q, Anghelina M, Neal J, Blachly JS, Rogers KA, Lozanski G, Oakes CC, Bhat SA, Zent CS, Banerji V, Grever M, Andritsos L (2023). Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis. American journal of hematology, 98(5), E116-E118. (Read full publication)
    12. Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzmán A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, Olszewski A (2023). Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. Journal of hematology & oncology, 16(1), 49. (Read full publication)
    13. Epperla N, Zhao Q, Moyo T, Watkins MP, Tavakkoli M, Bello C, Torka P, Reddy N, Thomas C, Annunzio K, Christian B, Barta SK, Shouse G, Olszewski AJ, Bartlett N (2024). Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis. [Letter to the Editor]. Blood advances, 8(3), 549-552. (Read full publication)
    14. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali (2023). Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. Journal of hematology & oncology, 16(1), 111. (Read full publication)
    15. Vaughn JL, Epperla (2023). Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study. Biomarker research, 11(1), 84. (Read full publication)
    16. Epperla N, Nastoupil LJ, Feinberg B, Galvin J, Pathak P, Amoloja T, Gentile D, Saverno (2025). Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Biomarker research, 13(1), 18. (Read full publication)
    17. Chowdhury SM, Bhatta S, Voorhees TJ, Annunzio K, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Christian B, Jones D, Epperla (2025). Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma. Journal of hematology & oncology, 18(1), 4. (Read full publication)
    18. Umyarova E, Pei C, Pellegrino W, Zhao Q, Sharma N, Benson D, Cottini F, Bezerra E, Brammer J, Bumma N, Choe H, Denlinger N, Devarakonda S, Khan A, Penza S, Rosko A, Vasu S, Wall S, Alinari L, Baiocchi R, Bond DA, Christian B, Hanel W, Maddocks K, Reneau J, Sawalha Y, Habib A, Sigmund A, Voorhees TJ, de Lima M, Epperla (2025). Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies. Journal of hematology & oncology, 18(1), 30. (Read full publication)
    19. Borja-Montes OF, Toro-Pedroza A, Epperla N, Andritsos L (2025). Hairy cell leukaemia and pregnancy: A systematic review and review of literature. British journal of haematology, (Read full publication)
    20. Epperla N, Shouse G, Grover NS, Torka P, Annunzio K, Watkins M, Anampa-Guzmán A, Christian B, Thomas C, Barta SK, Geethakumari PR, Karmali R, Bartlett NL, Olszewski A (2025). Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study. Experimental hematology & oncology, 14(1), 73. (Read full publication)
    21. Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla (2025). Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States. Biomarker research, 13(1), 64. (Read full publication)
    22. Trabolsi A, Han S, Epperla N, Annunzio K, Baidoun F, Alhaj Moustafa M, Morgenstern-Kaplan D, Doukas P, St-Pierre F, McCall B, Fitzgerald L, Sandoval-Sus J, Dalal S, Reis IM, Chapman-Fredricks JR, Kim SH, Au C, Otto NB, Alhamad K, Ollila T, Karmali R, Shouse G, Lossos IS, Alderuccio J (2024). Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study. Blood neoplasia, 2(1), 100063. (Read full publication)
    23. Sayed A, Munir M, Poliner M, Sughra S, Epperla N, Addison (2024). Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi et al. Journal for immunotherapy of cancer, 12(4), (Read full publication)
    24. Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, Bhat SA, Blachly J, Broccoli A, Call T, Dearden C, Dietrich S, Else M, Epperla N, Fagarasanu A, Falini B, Forconi F, Gozzetti A, Hampel P, Hermel DJ, Iyengar S, Johnston JB, Juliusson G, Kreitman RJ, Lauria F, Lozanski G, Oakes CC, Parikh SA, Park J, Quest G, Rai K, Ravandi F, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Tiacci E, Troussard X, Wörmann B, Zent CS, Zenz T, Zinzani P (2024). Hairy cell leukemia variant and WHO classification correspondence Re: 5(th) edition WHO classification haematolymphoid tumors: lymphoid neoplasms. Leukemia, 38(7), 1642-1644. (Read full publication)
    25. Munir M, Vaughn JL, Rimmalapudi S, Epperla (2025). Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States. Blood cancer journal, 15(1), 201. (Read full publication)

    Abstract

    1. Maddocks K, Awan F, Huang Y, Ayyappan S, Baiocchi R, Epperla N, Jaglowski S, William B, Blum K, Christian (2018). Preliminary results of a phase I study of Obinutuzumab, venetoclax and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma. 132(Suppl 1), 4185.
    2. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, Fenske (2019). Post-relapse survival in Diffuse Large B-cell Lymphoma patients after experiencing therapy failure following autologous hematopoietic cell transplantation. 25(3), S22.
    3. Romancki J, Switchenko J, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta SK, Gordon M, Danilov A, Grover NS, Mathews M, Burkhart M, Karmali R, Swalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen (2019). The Impact of Pre-Diagnosis Tobacco use in Mantle Cell Lymphoma. 134(Suppll 1), 5891.
    4. MJ Cortese, MM Herr, N Nair, J Romancik, N Grover, RS Bhansali, C Thomas, TK Moyo, VP Kenkre, T Ollila, B Hess, L Fitzgerald, G Shouse, M Matasar, K Annunzio, JA Davis, C Jesme, A Pelcovits, M Melody, J Moreira, AY Lin, S Ma, JN Winter, A Niu, AV Danilov, NN Shah, DM Stephens, JB Cohen, LI Gordon, SK Barta, N Epperla, R Karmal (2024). Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis. American Society of Hematology (ASH Publication). (2024) 144 (Supplement 1)(525),
    5. Megan Melody, Natalie Grover, Stephanie Franco, Jason T Romancik, Matthew J Cortese, Tamara K Moyo, Rahul S Bhansali, Thomas Ollila, Vaishalee P Kenkre, Lindsey Fitzgerald, Brian Hess, Matthew Matasar, Geoffrey Shouse, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Shuo Ma, Jane N Winter, Adam Yuh Lin, Alexey Danilov, Ishan Roy, Stefan K. Barta, Leo I. Gordon, Deborah M. Stephens, Jonathon B Cohen, Narendranath Epperla, Reem Karmal (2024). Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma. American Society of Hematology (ASH Publication). (2024) 144 (Supplement 1)(473),
    6. Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Natalie Grover, Jason T Romancik, Matthew J Cortese, Rahul S Bhansali, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alexey V. Danilov, Nirav N. Shah, Stefan K. Barta, Jonathon B Cohen, Leo I. Gordon, Deborah M. Stephens, Reem Karmal (2024). Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy. American Society of Hematology (ASH Publication). (2024) 144 (Supplement 1)(612),
    7. K. Kim, X. Sun, T. Voorhees, Y. Youssef, N. Epperla, M. De Castro, K. Ow, M. Santiago, J. Varghese, A. Ayers, M. Hawkins, V. Leautaud, J. Ramdial, P. Kebriaei, E. Shpall, H. Liu, M. Jain, J. Chavez, F. Locke, N. Sattva, S. Ahmed, S. Paol (2025). 456 | Identification Of An Optimal Absolute Lymphocyte Count Before Leukapheresis In Large B'Cell Lymphoma Patients Treated With Cart. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    8. A. M. Bock, K. Baron, C. Wagner, L. Fitzgerald, D. Ermann, B. Hu, H. Shah, J. Zak, N. Epperl (2025). 504 | Impact Of The Neutrophil/Lymphocyte Ratio On Outcomes Following Bispecific Antibody Therapy In Relapsed/Refractory Lymphoma Patients. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    9. Baron K., Wagner C., Fitzgerald L.A., Ermann D.A., Hu B., Epperla N., Shah H.A. and Bock A. (2025 (2025). 620 | A Standardized Process For A Rapid Dose Escalation Of Epcoritamab For Patients With Lymphoid Malignancies In The United States. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    10. A. M. Bock, L. Feng, A. Ayers, A. Chauhan, S. Thiruvengadam, A. Jallouk, C. D'Angelo, Y. Sawalha, S. Godbole, R. Merryman, S. Bhaskar, K. Baron, M. Lunning, A. Herrera, J. L. Crombie, N. Epperla, S. Ahme (2025). 667 | Real'World Safety And Efficacy Of Epcoritamab For Patients With Relapsed/Refractory Large B'Cell Lymphomas. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    11. G. Shouse, S. Ahmed, L. Chen, G. Salles, A. M. Bock, M. A. Lunning, S. Godbole, Y. Sawalha, A. A. Ayers, S. Thiruvengadam, C. Goth, C. R. Flowers, A. Chauhan, N. Epperla, A. Herrera, A. V. Danilov, L. Falch (2025). 671 | Glofitamab For The Treatment Of Relapsed/Refractory Diffuse Large B Cell Lymphoma, A Real'World Evidence Study From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    12. S. K. Thiruvengadam, L. Chen, S. Ahmed, A. Bock, N. Epperla, S. Godbole, Y. Sawalha, A. Jallouk, S. Bhaskar, L. Falchi, G. Salles, M. Lunning, J. Crombie, R. Merryman, A. A. Ayers, C. Goth, G. Shouse, C. Flowers, A. Danilov, A. F. Herrera, A. Chauha (2025). 161 | Outcomes Of Glofitamab And Epcoritamab In R/R Dlbcl Elderly Patients: A Real'World Evidence Study From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    13. D. Baggio, S. Han, P. Ghione, I. Okcu, J. Okosun, M. Kamdar, A. Kuhnl, N. Grover, H. Cherng, A. Olszewski, P. Ramakrishnan Geethakumari, J. Smith, A. Prica, J. Khwaja, W. Osborne, J. Koff, D. El-Sharkawi, N. Wagner-Johnston, J. Munoz, A. Desai, N. Epperla, F. Baidoun, T. Moyo, M. Narkhede, A. Barrett, K. Linton, D. Wallace, N. Elmusharaf, J. Sandoval-Sus, A. Danilov, J. Rhodes, A. Santarsieri, F. Karim, J. Calabrese De Feo, R. Tavarozzi, I. Nizamuddin, N. Dong, A. Saha, W. Hann, Y. Wang, R. Treitman, A. Maraj, S. Tolu, T. Ollila, C. Abeyakoon, V. Calvert, A. Ayers, A. Hilali, I. Trutzer, S. Monick, J. Sharp, H. Tun, N. Ghosh, G. P. Collins, V. Deshani, J. Can, A. Kallam, B. Kahl, J. Chavez, K. Cwynarski, J. P. Alderucci (2025). 339 | Outcomes In An International Multicentre Study Of 600 Patients With CNS Relapse Of Large B Cell Lymphoma: Compartment Of Relapse Is Prognostic. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    14. P. Stephan, K. L. Chohan, R. A. Redd, S. Ahmed, C. R. Flowers, A. Chauhan, A. A. Ayers, G. Shouse, S. K. Thiruvengadam, A. F. Herrera, A. M. Bock, N. Epperla, S. M. Buckley, B. Hu, M. A. Lunning, G. Salles, L. Falchi, Y. Sawalha, S. Godbole, A. P. Jallouk, S. T. Bhaskar, P. Armand, R. W. Merryman, J. L. Crombie, A. V. Danilo (2025). 243 | Real'World Outcomes Of Cd20xcd3 Bispecific Antibody Therapy In Adult Patients With Relapsed/Refractory Transformed Indolent Lymphoma. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    15. A. Jallouk, L. Feng, A. Ayers, A. Chauhan, S. Thiruvengadam, A. Bock, S. Bhaskar, N. Epperla, A. Herrera, S. Ahme (2025). 566 | Real-World Outcomes Of Mosunetuzumab Use From The Cubic Consortium. 18th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 2025. 43(S3),
    16. MJ Cortese, MM Herr, NM Nair, JT Romancik, DM Stephens, R Bhansali, TK Moyo, VP Kenkre, T Ollila, BT Hess, L Fitzgerald, G Shouse, M Matasar, J Davis, C Jesme, A Pelcovits, J Moreira, AY Lin, S Ma, J Winter, AV Danilov, NN Shah, SK Barta, JB Cohen, LI Gordon, N Epperla, N Grover, R Karmali (2025). 303 | Clinical Outcomes of Transformed Marginal Zone Lymphoma and Richter Transformation with CAR T-Cell Therapy: A US Multicenter Real-World Analysis. Abstracts from the 2025 Tandem Meetings of ASTCT and CIBMTR, February 2025, Honolulu, Hawaii. 31(2 (Supplement)), S224-S225.
    17. N Epperla, B Adedokun, H Hashmi, M Shadman, AM Winter, AF Herrera, M Hamadani, C Jacobson, N Ahmed, W Perez, Z Feng, K Hu, B Du, J Kim, T Best, A Baer, A Pradhan, MC Pasquini, and S Ahme (2025). 7024| Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL). 2025 ASCO Annual Meeting, Chicago, IL. 43(16_Supplement),
    18. Epperla N, Zhao Q, Anghelina M, Neal J, Blachly JS, Rogers KA, Lozanski G, Oakes C, Bhat S, Banerji V, Zent C, Grever MR, and Andritsos L (2022). Impact of sex on outcomes in patients with hairy cell leukemia (HCL): An HCL patient data registry analysis. ASCO Annual Meeting; June 2022. Chicago, IL. 40(16_Supplement), 7577-7577.
    19. David KA, Sundaram S, Kim S, Vaca R, Lin Y, Singer S, Malecek M, Carter J, Zayac A, Kim MS, Reddy N, Habib A, Strouse C, Graber J, Bachanova V, Tsang M, Major A, Bond D, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Glantz M, Goldlust S, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM (2021). Older patients with primary CNS lymphoma: Real world outcomes of post-induction therapy in the modern era. International Conference on Malignant Lymphoma (ICML); June 2021. (virtual). 39(2),
    20. TS Oh, MM Herr, N Grover, JT Romancik, N Epperla, MJ Cortese, R Bhansali, TK Moyo, VP Kenkre, NM Nair, T Ollila, BT Hess, L Fitzgerald, G Shouse, M Matasar, J Davis, C Jesme, A Pelcovits, J Moreira, A Lin, S Ma, J Winter, AV Danilov, NN Shah, SK Barta, JB Cohen, LI Gordon, DM Stephens, R Karmal (2025). 59 | A Comparison of Survival in Younger Vs Older Patients Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) for Aggressive B-Cell Lymphoma. Abstracts from the 2025 Tandem Meetings of ASTCT and CIBMTR, February 2025, Honolulu, Hawaii. 31(2 (Supplement)), S46-S47.
    21. A Shaaban, A Habib, S Ghazi, S Sharma, A Salem, M Ferdousi, P Ruz, N Epperla, D Addiso (2025). 4369783| Clinical Safety Outcomes of ICI Rechallenge following ICI-myocarditis and other Cardiotoxicities. 152(3),
    22. E. Scheffer Cliff, G. Pelaez, F. Wan, V. Iyengar, J. Zhou, K. Chung, N Abdel-Razeq, J. Allen; A. Major, J. Sharp, N. Epperla, P. Gould, H. Cherng, S. Houshyar, D. Wallace, R. Lynch, A. Kallam, M. Mei, R. Merryman, M. Fleyshman, J. Rhodes, A. Kidwell, T. Fenske, N. Malakhov, E. Mulvey, M. Watkins, M. Moustafa, T. Halal, G. Nowakowski, Y. Wang, P. Torka, D. Russler-Germai (2025). Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma.
    23. N. Altomare, M. Herr, N. Nair, D. Stephens, N. Epperla, M. Cortese, R. Bhansali, T. Moyo, V. Kenkre, T. Ollila, B. Hess, L. Fitzgerald, G. Shouse, J. Davis, C. Jesme, A. Pelcovits, J. Moreira, A. Lin, S. Ma, J. Winter, A. Danilov, S. Barta, J. Cohen, L. Gordon, J. Romancik, N. Grover, R. Karmal (2025). 545| Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART. 31(2, Supplement), S387-S388.
    24. Kenkre VP, Lin Y, Epperla N, Rajguru SA, Chang JE, Pophali PA, Harris EI, Fletcher CD, Matasar M, Eltoukhy H, Bond DA, Sawalha Y, Christian B, Voorhees T, Endres M, Howard M, Bhavsar D, Fleming M, Carter JS, Evens A (2024). 623| A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study. 144(Supplement 1), 4415.
    25. J Sharp, P Strati, S Bhatta, J Huang, C Thomas, D Reff, A Gorzewski, C Reinert, A Teferra, A Pelcovits, T Ollila J Maakaron, M Kamdar, L Fitzgerald, R Karmali, N Grover, S Barta, T Voorhees, M Shadman, S Ahmed, N Epperl (2024). 906| Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers. 144(Supplement 1),
    26. D Bond, Y Huang, J Reneau, Y Sawalka, J Brammer, T Voorhees, N Epperla, A Sigmund, L Alinari, W Hanel, A Gilmore, M Fleming, K Stamper, R Baiocchi, B Christian, K Maddock (2024). Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial. 144(Supplement 1),
    27. K Saverno, L Nastoupil. B Feinberg, J Galvin, P Pathak, T Amoloja, D Gentile, P Asgarisabet, N Epperl (2024). Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States. 144(Supplement 1),
    28. J Sharp, S Bhatta, N Takacs, K Tong, Y Youssef, D Bond, Y Sawalha, A Sigmund, L Sehgal, L Alinari, R Baiocchi, K Maddocks, B Christian, T Voorhees, N Epperla (2024). Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM). 144(Supplement 1),
    29. A Ramdhanny, J Vaughn, N Epperla (2024). Impact of Chimeric Antigen Receptor T-Cell Therapy on Survival in Patients with Diffuse Large B-Cell Lymphoma at the Population Level in the United States. 144(Supplement 1),
    30. J Wang, J Zhou, Y Wang, J Munoz, K Shim, MA Moustafa, F Baidoun, K Annunzio, N Epperla, M McClane, Y Karimi, Binh Luu, S Spurgeon, C Chang, Z Wan, D Gathers, E King, M Watkins, N Bartlett, C Ryan, G Gerhard, P Armand, A LaCasce, V Vaddaraju, D Wallace, V Kenkre, C Junge, N Grover, J Florindez, R Karmali, A Stanisic, C Zhang, P Venugopal, G Ying, C Gribbin, J Ruan, N Shakula, S Smith, V Zelikson, M Williams, S Barta, O Elghawy, J Schade, R Navalekar, M Matasar, A Evens, A Danilov, T Fenske (2024). Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutates Mantle Cell Lymphoma. 144(Supplement 1),
    31. J Vaughn, N Epperl (2024). Trends in Incidence and Survival of Patients with Primary Effusion Lymphoma in the United States. 144(Supplement 1),
    32. F St-Pierre, S Bhatta, P Doukas, M Jenkin, K Annunzio, A Rojek, YK Tiger, B McCall, K Alhamad, A Hansen, JP Alderuccio, O Adewale, K Patel, A Trabolsi, I Lossos, L Fitzgerald, T Ollila, M Matasar, J Kline, R Karmali, N Epperl (2024). Outcomes of Chimeric Antigen Receptor (CAR) T-Cell therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis. 144(Supplement 1),
    33. N Epperla, N Grover, P Torka, R Karmali, K Annunzio, M Watkins, A Anampa-Guzman, H Reves, M Tavakkoli, B Christian, C Thomas, S Barta, P Ramakrishnan Geethakumari, G Shouse, N Bartlett, A Olszewsk (2024). Evaluation of Risk Factors for Histological Transformation in Patients with Marginal Zone Lymphoma (MZL): Results from a Multicenter Cohort Study. 144(Supplement 1),
    34. Y Wang, S Singh, A Odier, A La Ferlita, W Chan, M Berger, S Sreekanth, N Epperla, N Mathusamy, R Baiocchi, L Alinari, M Gupta, L Sehgal (2024). Tumor Microenvironment-Induced Interleukin-6 Regulates Proliferation and Survival in Patients with Mantle Cell Lymphoma (MCL) By Activating FGFR1 Signaling. 144(Supplement 1), 4371.
    35. MJ Tariq, K Attwood, A Anampa-Guzman, S Hamid, A Niu, D Kaldas, S Thapa, J Leng, Y Youssef, K Carroll, R Treitman, A Rafae, S Singhal, S Nakhoda, S Al Hadidi, S Bair, T Voorhees, N Epperla, P Caimi, A Grajales-Cruz, F Hernandez-Ilizaliturri, M Cortes (2024). Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis. 144(Supplement 1), 4392.
    36. J Sharp, Q Zhao, T Voorhees, D Bond, Y Sawalha, J Reneau, A SIgmund, W Hanel, L SEhgal, L Alinari, R Baiocchi, J Brammer, K Maddocks, B Christian, E Bezzera, N Denlinger, S Vasu, M de Lima, J Prosek, N Epperl (2024). Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma. 144(Supplement 1), 3747.
    37. S Singh, A La Ferlita, N Jain, M Berger, S Sreekanth, R Distefano, M Gupta, N Muthusamy, R Baiocchi, L Alinari, N Epperla, L Sehgal (2024). Transcriptomic Analysis in Mantle Cell Lymphoma Patients Identified MALAT1 Long-Non-Coding RNA to Regulate Cell Cycle Progression By Modulating EZH2/p57/Sox11 Axis. 144(Supplement 1), 4350.
    38. OB Montes, A Jawadi, S Varatharaj, H Herring, TE Gil, N Epperla, L Andritso (2024). Evaluation of Measurable Residual Disease Assessment Dynamics in Hairy Cell Leukemia Clinical Trials from 1980 to 2020. 144(Supplement 1), 7787.
    39. X Lu, A Bokun, C Yang, Y Wang, W Chen, J Wang, N Epperl (2024). Estimating and Projecting the Number of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) By Treatment Lines in the United States. 144(Supplement 1), 7618.
    40. jP Alderuccio, J Khwaja, S Han, P Ghione, I Nizamuddin, A Saha, N Dong, Y Wang, HJ Cherng, S Tolu, N Wagner-Johnston, A Olszewski, N Grover, J Koff, A Desai, P Ramakrishnan Geethakumari, T Moyo, J Sandoval-Sus, N Epperla, D Wallace, M Kamdar, A Danilov, H Tun, J Munoz, M Narkhede, J Rhodes, A Prica, A Kuhnl, A Maraj, J Okosun, J Smith, W Osborne, V Calvert, D el-Sharkawi, A Hilali, G Collins, K Linton, N Elmusharaf, S Santarsieri, F Karim, T Ollila, S Monick, IM Trutzer, N Ghosh, J Can, A Ayers, J Calabrese De Feo, J Sharp, R Treitman, A Kallam, Izel Okcu, Vismay Deshani, F Baidoun, C Abeyakoon, W Hann, A Barrett, B Kahl, J Chavez, K Cwynarsk (2024). Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort. 144(Supplement 1), 571.
    41. E Scheffer Cliff, G Pelaez, F Wan, V Iyengar, J Zhou, K Chung, N Abdel-Razeq, A Major, J Allen, J Sharp, N Epperla, P Gould, HJ Cherng, S Houshyar, D Wallace, R Lynch, A Kallam, M Mei, R Merryman, M Fleyshman, J Rhodes, A Kidwell, T Fenske, E Mulvey, M Watkins, MA Moustafa, T Hilal, G Nowakowski, Y Wang, P Torka, D Russler-Germai (2024). The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin. 144(Supplement 1), 652.
    42. S Vasu, E Bezzera, N Denlinger, N Szuminski, D Schneider, P Dash, L Wirthlin, N Epperla, Y Sawalha, J Woyach, K Rodgers, S Bhat, G Behbehani, K Larking, A Kittai, W Chan, A Krull, S Nishat, L O'Donnell, L Alinari, M de Lima (2024). Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies. 144(Supplement 1), 2078.
    43. I Nizamuddin, N Epperla, MK Malacek, B Kahl, F Wan, A Fischer, C Moreno, E King, A Krivenko, N Bartlett, N Mehta-Shah (2024). Phase I Results of Acalabrutinib in Combination with Durvalumab in Primary Central Nervous System Lymphoma: Safety, Efficacy, and Central Nervous System Penetration. 144(Supplement 1), 985.
    44. A Alencar, O Bobek, N Mehta-Shah, N Epperla, C Lu-Emerson, S Rutherford, A Olszewski, T Ollila, S Singer, T Dockter, S Geyer, L Rosenstein, M De La Fuente, E Hsi, S Dinner, J Rubenstein, N Bartlett, J Leonard (2024). Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). 144(Supplement 1), 4502.4.
    45. S Neelapu, J Chavez, A Sehgal. N Epperla, M Ulrickson, E Bachy, P Munshi, C Casulo, D Malone, S de Vos, R Reshef, L Leslie, O Oluwole, I Yakoub-Agha, R Khanal, J Rosenblatt, J Wulff, R Shen, W Zhang, S Poddar, H Miao, O Nikolajeva, C Jacobso (2024). 5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. 144(Supplement 1), 864.
    46. N Epperla, M Lucero, T Bailey, L Mirams, J Cheung, M Amet, G Milligan, C Keir, L Che (2024). ABCL-370 Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T-Cell Therapy in the US. 24(Supplement 1), S476.
    47. N Epperla, L Nastoupil, B Feinberg, J Galvin, P Pathak, T Amoloja, D Gentile, K Savern (2024). ABCL-406 Real-World Sequential Use of CD19-Directed Therapies for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab Preceding Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. 24(Supplement 1), S477.
    48. N Epperla, LJ Nastoupil, KMZ Savill, K Zimmerman, B Feinberg, J Galvin, P Pathak, T Amoloja, M Vukcevic, K Savern (2024). ABCL-206: Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years). 46(Supplement 4), S213.
    49. I Nizamuddin, B Kahl, N Bartlett, N Epperla, N Mehta-Sha (2024). Trial in Progress: Phase 1 Study with Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary Central Nervous System Lymphoma. 24(Supplement 1), S219.
    50. K Sverno, K Zimmerman, B Feinberg, J Galvin, P Pathak, T Amoloja, N Epperla, L Nastoupi (2024). ABCL-207: Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status. 24(Supplement 1), S213.
    51. I Nizamuddin, B Kahl, N Bartlett, N Epperla, N Mehta-Sha (2024). ABCL-607: Trial in Progress: Phase 1 Study with Dose Expansion of Acalabrutinib and Durvalumab (MEDI 4736) in Primary Central Nervous System Lymphoma. 24(Supplement 1), S484-S486.
    52. A Habib, R Welkie, J Butman, P Silberman, J Forero, Y Sawalha, B Christian, K Maddocks, N Epperla, S Jaglowski, D Bond, H Choe, J Brammer, A Kittai, E Bezerra, T Voorhees, S Vasu, S Wall, M De Lima, N Denlinge (2024). Secondary Myeloid Malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL). 42(Number 16 Supplemental), 7033.
    53. George, Z Durisek, T Voorhees, N Denlinger, N Epperla, A Sigmund, G Sanches-Petitto, Y Sawalha, D Bond, H Choe, S Wall, J Brammer, L Alinari, B Christian, S Cataland, S Jagloqski, K Maddocks, M De Lima, S Vasu, E Bezerra (2024). Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell-associated neurotoxicity syndrome (ICANS). 42(Number 16 Supplemental), 7036.
    54. G McNally, M Xu, T Voorhees, R Baiocchi, D Bond, N Epperla, K Maddocks, Y Sawhala, B Ramaswamy, M Lustber (2024). Neurofilament light chains: A biomarker for vincristine-related neuropathy. 42(Number 16 Supplemental), 12114.
    55. S Singh, A Sircar, A Odier, N Epperla, N Muthusamy, S Parekh, L Sehga (2024). Abstract 3165: Targeting angiogenesis for improved survival in mantle cell lymphoma. 84(Supplement 6), 3165.
    56. A LaFerlita, S Singh, A Sircar, R Baiocchi, N Muthusamy, L Alinari, N Epperla, L Sehga (2024). Abstract 2997: Identification of novel long non-coding RNAs in mantle cell lymphoma patients. 84(Supplement 6), 2997.
    57. H Hashimi, N Epperla, K Ahn, M Allbee-Johnson, S Mercadal, C Lee, M Shadman, C Sauter, M Hamadani, A Herrera, S Ahme (2024). Abstract 48: Outcomes of Large B-Cell Lymphoma (LBCL) Patients with Secondary Central Nervous System Involvement Following Chimeric Antigen Receptor T-Cell Therapy: A CIBMTR Analysis. 30(2 Supplement), S42.
    58. T Voorhees, Y Huang, N Denlinger, N Epperla, J Brammer, Y Sawalha, D Bond, E Bezerra, T Needham, J Reneau, A Sigmund, W Hanel, L Alinari, B Christian, R Baiocchi, K Maddocks, S Jaglowski, S Vasu, M de Lima, P Caim (2024). Abstract 486: Siltuximab Prophylaxis Prior to Standard of Care CD19 Directed Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: Interim Results from a Phase 1 Clinical Trial. 30(2 Supplement), S355-S356.
    59. A Bajwa, Q Zhao, M Geer, A Mian, C Lin, D Frame, J Westholder, J Tossey, M Ghosh, A Galal, N Ahmed, J Maakaron, N Denlinger, M de Lima, N Epperla, P Caimi, T Voorhee (2024). Abstract 261: Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities - a Multicenter Retrospective Analysis. 30(2 Supplement), S201-S202.
    60. S Abedin, S Chhabra, N Epperla, W Longo, M Pasquini, K Peterson, T Fenske, L Runaas, N Shah, M Hamadan (2024). Abstract 217: Reduced Intensity Conditioning (RIC) Transplant with Very Low Dose Evomela Is Safe and Effective in Patients with Hematologic Malignancies Undergoing Haploidentical Donor Transplant. 30(2 Supplement), S167-S168.
    61. N Epperla, M Lucero, T Bailey, L Mirams, J Cheung, M Amet, G Milligan, Lei Che (2024). Abstract 482: Real-World Clinical Effectiveness of Loncastuzimab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Following Chimeric Antigen T Cell Therapy in the US. 30(2 Supplement), S353.
    62. a sayed, m munir, s Ghazi, m Ferdousi, S Krishan, A Shaaban, A Habib, O Kola, Kehinde, P Ruz, S Khan, S Sharma, A Meara, S Mahmood, S Feldman, E Yang, J Kim, N Epperla, D Addiso (2024). Cardiovascular toxicities associated with bispecific T-cell engager therapy. 12(2),
    63. Y Sawalha, R Welkie, A Krivenko, B Hess, A Sigmund, T Voorhees, W Hanel, D Bond, J Reneau, N Epperla, L Alinari, J Brammer, B Christian, R Baiocchi, K Maddock (2023). Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Predinisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial. . 142(Supplement 1), 6226.
    64. A Lehanka, A Kebede, N Amirmokhtari, J Stanek, N Epperla, B Christian, R Baiocchi, T Voorhees, K Maddocks, Y Sawalha, J Reneau, J Brammer, A Sigmund, F Willen, N Yeager, A Audino, D Bon (2023). Differences in Observed Toxicities for Adolescent and Young Adult Patients with Aggressive Mature B-Cell Lymphomas Treated with Adult Versus Pediatric Cancer Center - a Comparative Cohort Study. 142(Supplement 1), 3116.
    65. N Epperla, K Annunzio, G Shouse, N Grover, P Torka, M Watkins, A Anampa-Guzman, T Oh, H Reves, M Tavakkoli, E Hansinger, B Christian, C Thomas, S Barta, P Ramakrishnan Geethakumari, R Karmali, N Bartlett, A Olszewsk (2023). Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. 142(Supplement 1), 5147.
    66. T Voorhees, N Grover, E McLaughlin, J Florindez, T Mayo, H Reves, N Sumransub, S Deshpande, A Rose, C Duarte, MS Faisal, S Hamid, S Subbiah, S Ayyappan, L Shea, M Cortese, K Patel, A Major, H Saeed, J Svoboda, S Desai, P Ramakrishnan Geethakumari, P Torka, N Epperl (2023). Allogeneic Stem Cell Transplant and CD30 Directed CART Cell Therapies Are Associated with Improved Survival in Classical Hodgkin Lymphoma Refractory or Intolerant Brentuximab Vedotin and Anti-PD-1 Therapy: Real World Ananlysis from 14 U.S. Academic Centers. . 142(Supplement 1), 900.
    67. N Epperla, L Nastoupil, K Zimmerman Savill, B Feinberg, J Galvin, P Pathak, S Gordon, T Llorente, K Savern (2023). Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States. 142(Supplement 1), 2415.
    68. N Epperla, K Annunzio, G Shouse, N Grover, P Torka, M Watkins, A Anampa-Guzman, T Oh, H Reves, M Tavakkoli, E Hansinger, B Christian, C Thomas, S Barta, P Ramakrishnan Geethakumari, R Karmali, N Bartlett, Olszewsk (2023). Impact of Diagnosis to Treatment Interval on Outcomes in Patients with Newly Diagnosed Marginal Zone Lymphoma - a US Multisite Study. 142(Supplement 1), 5159.
    69. K Saverno, K Zimmerman Savill, B Feinberg, J Galvin, P Pathak, S Gordon, T Amoloja, M Llorente, N Epperla, L Nastoupi (2023). Abstract 265: Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting. 142(Supplement 1), 265.
    70. S Neelapu, J Chavez, A Sehgal, N Epperla, M Ulrickson, E Bachy, P Munshi, C Casulo, D Maloney, S de Vos, R Reshef, L Leslie, O Oluwole, I Yakoub-Agha, R Khanal, J Rosenblatt, W Peng, C Lui, J Wulff, R Shen, S Poddar, A Lee, H Miao, O Nikolajeva, C Jacobso (2023). Abstract 4868: Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. 142, 4868.
    71. A Trabolsi, N Epperla, K Annunzio, D Morgenstern Kaplan, P Doukas, F St-Pierre, B McCall, L Fitzgerald, S Han, I Reis, J Chapman-Fredericks, K Alhamad, T Ollila, R Karmali, I Lossos, J Alderucci (2023). Abstract 3770: A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma. 142(Supplement 1), 3770.
    72. N Epperla, J Switchenko, S Geyer, V Bachanova, S Barta, A Danilov, N Grover, R Karmali, B Hill, N Ghosh, T Fenske, P Martin, B Kahl, C Flowers, B Link, E Hsi, K Maddocks, K Blum, T Habermann, M Maurer, L Kaplan, N Bartlett, J Leonard, J Cohe (2023). Abstract 380: Ki-67 Expression of 50% is the Optimal Cut-Off to Predict Survival Outcomes in Mantle Cell Lymphoma (MCL): A Pooled Analysis from CALGB 50403 (Alliance) and MCL Real-World Study Cohort. 142(Supplement 1), 380.

    Other

    1. Anghelina M, Naughton MJ, Zhao Q, Ruppert AS, Neal J, Rogers KA, Blachly JS, Lozanski G, Bhat SA, Kraut E, Epperla N, Mathur P, Zent CS, Banerji V, Dearden C, Hutchinson T, Grever M, Andritsos L (2022). Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919]. Leukemia research, 121, 106943. (Read full publication)

    Video/Film/CD/Web/Podcast

    1. Epperla (2021). Epperla Elucidates on Excitement With Tafasitamab and Selinexor in DLBCL. Dr. Epperla expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline. .
    2. Epperla (2021). Dr. Epperla on the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia .